TrialJournal of the European Academy of Dermatology and Venereology : JEADV2016

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.

A B Kimball et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.